10-K: Champions Oncology Reports FY2026 Results, Revenue Up 4%

Champions Oncology, Inc. announced its fiscal year 2026 results, reporting a 4.4% increase in revenue to $59.4 million, driven by growth in pharmacology services, despite a net loss for the year.

Summary

• Champions Oncology, Inc. reported total revenue of $59.4 million for the fiscal year ended April 30, 2026, a 4.4% increase from the prior year.
• The company experienced a net loss of $1.2 million for the fiscal year, compared to a net income of $4.7 million in the previous year.
• Research and development expenses increased by 33.1% to $9.1 million, and sales and marketing expenses rose by 23.5% to $9.3 million.
• The company's cash balance stood at $4.9 million as of April 30, 2026, with management believing it is adequate to fund operations through at least August 2027.
• Deferred revenue decreased significantly by $6.6 million, impacting cash flow from operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the shift from profitability to a net loss, increased operating expenses, and a significant decrease in deferred revenue, despite modest revenue growth.

Positives

• Total revenue increased by 4.4% to $59.4 million for the fiscal year ended April 30, 2026.
• Pharmacology services revenue saw an increase, driven by improved conversion of booked studies.
• The company expanded its data licensing customer base.
• The company believes its current cash on hand is adequate to fund operations through at least August 2027.

Negatives

• The company reported a net loss of $1.2 million for the fiscal year ended April 30, 2026, a significant shift from the $4.7 million net income in the prior year.
• Cost of oncology revenue increased by 8.8% to $30.9 million.
• Research and development expenses increased by 33.1% to $9.1 million.
• Sales and marketing expenses increased by 23.5% to $9.3 million.
• General and administrative expenses increased by 19.4% to $11.2 million.
• Deferred revenue decreased by $6.6 million, impacting cash flow from operations.
• The company has an accumulated deficit of $81.1 million as of April 30, 2026.

Risks

• The company historically incurred losses and may require significant capital, with no assurance of achieving sustained profitability.
• Failure to obtain sufficient capital from operations or external sources could lead to cessation of operations.
• The company's laboratories are subject to regulation and licensure requirements, and failure to comply could result in substantial penalties.
• The company relies on key employees, and the loss of their services could have a material adverse effect.
• The company faces intense competition from larger entities with greater resources.
• Intellectual property protection is crucial, and the company's TumorGraft Technology Platform is proprietary but not patented, posing a risk of competitors developing similar procedures.
• Claims of patent infringement could lead to costly litigation and diversion of resources.
• Research service studies are subject to cancellation based on changes in customer development plans.

Future Outlook

The company believes its current cash on hand, along with expected cash flows from operations, is sufficient to fund operations through at least August 2027. However, there is no assurance that additional capital can be raised on acceptable terms if needed.

Management Comments

• The company believes that its cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least August 2027.
• Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.

Industry Context

StockSavvy.ai notes that Champions Oncology operates in the highly competitive oncology research and drug development sector. The company's focus on proprietary PDX models and data-driven platforms positions it within a growing but crowded market, where innovation and speed are critical for success against larger, well-funded competitors.

Comparison to Industry Standards

• The company's revenue growth of 4.4% for FY2026 is modest compared to the rapid growth often seen in emerging biotech firms, but it indicates stability in its core research services.
• The significant increase in R&D spending (33.1%) suggests a strategic investment in future growth, aligning with industry trends of increased investment in novel therapeutic targets and platforms.
• The net loss for the year, while a negative, is not uncommon for companies in the drug discovery and development phase, which often require substantial upfront investment before commercialization.

Legal Proceedings

• To the knowledge of management, there is no litigation currently pending or contemplated against the company, its officers, or directors in their capacity as such, or against any of its property.

Related Party Transactions

• For fiscal years ended April 30, 2026 and 2025, the Company paid a member of its Board of Directors $0 and $12,000, respectively, for consulting services unrelated to his duties as a board member.

Stakeholder Impact

• Shareholders: The net loss and increased expenses may negatively impact shareholder value. The company's ability to raise future capital could lead to dilution.
• Employees: Increased R&D and sales/marketing expenses may indicate continued investment in personnel and growth initiatives. However, the net loss could create uncertainty.
• Customers: Continued revenue growth in research services suggests ongoing demand for the company's offerings. The company's investment in new technologies may benefit customers in the long term.
• Suppliers: Increased cost of oncology revenue, particularly outsourced laboratory costs, may impact supplier relationships and costs.

Next Steps

• Continue to build out the TumorBank by accessing patients with prioritized tumor subtypes and establishing novel PDX models.
• Add new experimental technologies to the platform, including expanding capabilities for radiopharmaceutical therapies and developing sophisticated analytical platforms.
• Invest in computational power, novel artificial intelligence, data structures, and analytics to better understand cancer and develop novel therapeutics.
• Evaluate strategic options for the drug discovery business, including potential spin-outs, licensing, or capital raises.

Key Dates

Recommendation

The company shows revenue growth in its core services, but the shift to a net loss, increased operating expenses, and a significant decrease in deferred revenue are concerning. While the company believes it has sufficient liquidity for the near term, the need for potential future capital raises and the competitive landscape warrant a cautious 'hold' stance until profitability improves and strategic initiatives show clearer traction.

Keywords

Oncology Research, Drug Discovery, Patient Derived Xenograft, PDX Models, Biotechnology, Pharmaceutical Services, Translational Oncology Solutions, SaaS